Views & Analysis Pandemic boost to decentralised trials is here to stay Due to the pandemic, decentralised trial solutions made the shift from an emerging trend to a crucial element of drug development.
Partner Content Partner Content Making the most of your remaining communications budget pharmaphorum connect's Mark Walmsley describes seven projects to maximise remaining communications budgets.
News J&J jumps on the MFN pricing train Johnson & Johnson is the latest pharma group to agree a Most-Favoured Nation (MFN) drug pricing deal with the Trump administration to avert tariffs.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.